HR+/HER2- Breast Cancer Clinical Trials

9 recruiting

HR+/HER2- Breast Cancer Trials at a Glance

11 actively recruiting trials for hr+/her2- breast cancer are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Zhengzhou, New York, and Nashville. Lead sponsors running hr+/her2- breast cancer studies include First Affiliated Hospital of Zhejiang University, Avenzo Therapeutics, Inc., and Henan Cancer Hospital.

Browse hr+/her2- breast cancer trials by phase

Treatments under study

About HR+/HER2- Breast Cancer Clinical Trials

Looking for clinical trials for HR+/HER2- Breast Cancer? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HR+/HER2- Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HR+/HER2- Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1Phase 2

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
Novartis Pharmaceuticals280 enrolled33 locationsNCT06726148
Recruiting
Phase 1Phase 2

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

HR+/HER2- Breast Cancer
Avenzo Therapeutics, Inc.380 enrolled11 locationsNCT06998407
Recruiting
Phase 1Phase 2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled4 locationsNCT07288359
Recruiting
Phase 2

QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer

Breast CancerHR+/HER2- Breast Cancer
Henan Cancer Hospital238 enrolled1 locationNCT06967103
Recruiting
Phase 1Phase 2

Study of AVZO-021 in Patients With Advanced Solid Tumors

Advanced Solid TumorHR+/HER2- Breast Cancer
Avenzo Therapeutics, Inc.430 enrolled13 locationsNCT05867251
Recruiting
Phase 2

Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University35 enrolled3 locationsNCT06874933
Recruiting
Phase 2

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University30 enrolled11 locationsNCT06611813
Recruiting
Phase 2

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

HR+/HER2- Breast Cancer
Henan Cancer Hospital357 enrolled1 locationNCT06860529
Recruiting
Phase 3

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University194 enrolled13 locationsNCT06977893
Recruiting
Phase 1Phase 2

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Advanced Solid TumorHR+/HER2- Breast Cancer
Beta Pharma (Suzhou) Co., Ltd.224 enrolled1 locationNCT04282031
Recruiting
Phase 3

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Advanced Breast CancerHR+/HER2- Breast Cancer
Fudan University184 enrolled1 locationNCT06447623